Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
Investor Presentations
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
Investor Presentations
Filter by Year:
2024
2023
2022
2021
15-Nov-2024
Investor presentation, 15 November 2024
7-Oct-2024
Investor webinar: Neuren continues PMS Phase 3 preparations following positive FDA meeting
19-Aug-2024
Investor roadshow presentation, 19 August 2024
9-Aug-2024
Investor webinar: NNZ-2591 Angelman syndrome Phase 2 trial top-line results
9-Aug-2024
NNZ-2591 Angelman top-line results presentation
29-May-2024
Corporate Presentation, 29 May 2024
28-May-2024
AGM webcast, 28 May 2024
28-May-2024
AGM Chair Address & CEO Presentation
27-May-2024
Investor webinar - Pitt Hopkins Phase 2 results, 27 May 2024
27-May-2024
Pitt Hopkins Phase 2 results presentation, 27 May 2024
1
2
Next
